Skip to main content
An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

GCC Agonist Signal in the Small Intestine

Major Program
Cancer Prevention Clinical Trials Network
Research Group
Gastrointestinal and Other Cancers
Sponsor
University of Wisconsin, Madison
Status
Active, not recruiting
NCT ID
NCT05107219
This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.
Intervention
Biopsy, Biospecimen Collection, Esophagogastroduodenoscopy, Linaclotide, Plecanatide
Condition
Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
Investigators
David S Weinberg, David S. Weinberg
CT Research Area
Prevention

See list of participating sites